Evaluation of an immunoassay for determination of plasma efavirenz concentrations in resource-limited settings

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Standard

Evaluation of an immunoassay for determination of plasma efavirenz concentrations in resource-limited settings. / Abdissa, Alemseged; Wiesner, Lubbe; McIlleron, Helen; Friis, Henrik; Andersen, Åse Bengård; Kæstel, Pernille.

I: International AIDS Society. Journal, Bind 17, 18979, 2014.

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Harvard

Abdissa, A, Wiesner, L, McIlleron, H, Friis, H, Andersen, ÅB & Kæstel, P 2014, 'Evaluation of an immunoassay for determination of plasma efavirenz concentrations in resource-limited settings', International AIDS Society. Journal, bind 17, 18979. https://doi.org/10.7448/IAS.17.1.18979

APA

Abdissa, A., Wiesner, L., McIlleron, H., Friis, H., Andersen, Å. B., & Kæstel, P. (2014). Evaluation of an immunoassay for determination of plasma efavirenz concentrations in resource-limited settings. International AIDS Society. Journal, 17, [18979]. https://doi.org/10.7448/IAS.17.1.18979

Vancouver

Abdissa A, Wiesner L, McIlleron H, Friis H, Andersen ÅB, Kæstel P. Evaluation of an immunoassay for determination of plasma efavirenz concentrations in resource-limited settings. International AIDS Society. Journal. 2014;17. 18979. https://doi.org/10.7448/IAS.17.1.18979

Author

Abdissa, Alemseged ; Wiesner, Lubbe ; McIlleron, Helen ; Friis, Henrik ; Andersen, Åse Bengård ; Kæstel, Pernille. / Evaluation of an immunoassay for determination of plasma efavirenz concentrations in resource-limited settings. I: International AIDS Society. Journal. 2014 ; Bind 17.

Bibtex

@article{1835e074b82e49afa1dae07142bf0c9b,
title = "Evaluation of an immunoassay for determination of plasma efavirenz concentrations in resource-limited settings",
abstract = "INTRODUCTION: Therapeutic drug monitoring (TDM) may improve antiretroviral efficacy through adjustment of individual drug administration. This could result in reduced toxicity, prevent drug resistance, and aid management of drug-drug interactions. However, most measurement methods are too costly to be implemented in resource-limited settings. This study evaluated a commercially available immunoassay for measurement of plasma efavirenz.METHODS: The immunoassay-based method was applied to measure efavirenz using a readily available Humastar 80 chemistry analyzer. We compared plasma efavirenz concentrations measured by the immunoassay with liquid chromatography tandem mass spectrometry (LC-MS/MS) (reference method) in 315 plasma samples collected from HIV patients on treatment. Concentrations were categorized as suboptimal<1 µg/ml, normal 1-4 µg/ml or high>4 µg/ml. Agreement between results of the methods was assessed via Bland-Altman plot and κ statistic values.RESULTS: The median Interquartile range (IQR) efavirenz concentration was 2.8 (1.9; 4.5) µg/ml measured by the LC-MS/MS method and 2.5 (1.8; 3.9) µg/ml by the immunoassay and the results were well correlated (ρ=0.94). The limits of agreement assessed by Bland-Altman plots were -2.54; 1.70 µg/ml. Although immunoassay underestimated high concentrations, it had good agreement for classification into low, normal or high concentrations (K=0.74).CONCLUSIONS: The immunoassay is a feasible alternative to determine efavirenz in areas with limited resources. The assay provides a reasonable approximation of efavirenz concentration in the majority of samples with a tendency to underestimate high concentrations. Agreement between tests evaluated in this study was clinically satisfactory for identification of low, normal and high efavirenz concentrations.",
author = "Alemseged Abdissa and Lubbe Wiesner and Helen McIlleron and Henrik Friis and Andersen, {{\AA}se Beng{\aa}rd} and Pernille K{\ae}stel",
note = "CURIS 2014 NEXS 205",
year = "2014",
doi = "10.7448/IAS.17.1.18979",
language = "English",
volume = "17",
journal = "International AIDS Society. Journal",
issn = "1758-2652",
publisher = "BioMed Central Ltd.",

}

RIS

TY - JOUR

T1 - Evaluation of an immunoassay for determination of plasma efavirenz concentrations in resource-limited settings

AU - Abdissa, Alemseged

AU - Wiesner, Lubbe

AU - McIlleron, Helen

AU - Friis, Henrik

AU - Andersen, Åse Bengård

AU - Kæstel, Pernille

N1 - CURIS 2014 NEXS 205

PY - 2014

Y1 - 2014

N2 - INTRODUCTION: Therapeutic drug monitoring (TDM) may improve antiretroviral efficacy through adjustment of individual drug administration. This could result in reduced toxicity, prevent drug resistance, and aid management of drug-drug interactions. However, most measurement methods are too costly to be implemented in resource-limited settings. This study evaluated a commercially available immunoassay for measurement of plasma efavirenz.METHODS: The immunoassay-based method was applied to measure efavirenz using a readily available Humastar 80 chemistry analyzer. We compared plasma efavirenz concentrations measured by the immunoassay with liquid chromatography tandem mass spectrometry (LC-MS/MS) (reference method) in 315 plasma samples collected from HIV patients on treatment. Concentrations were categorized as suboptimal<1 µg/ml, normal 1-4 µg/ml or high>4 µg/ml. Agreement between results of the methods was assessed via Bland-Altman plot and κ statistic values.RESULTS: The median Interquartile range (IQR) efavirenz concentration was 2.8 (1.9; 4.5) µg/ml measured by the LC-MS/MS method and 2.5 (1.8; 3.9) µg/ml by the immunoassay and the results were well correlated (ρ=0.94). The limits of agreement assessed by Bland-Altman plots were -2.54; 1.70 µg/ml. Although immunoassay underestimated high concentrations, it had good agreement for classification into low, normal or high concentrations (K=0.74).CONCLUSIONS: The immunoassay is a feasible alternative to determine efavirenz in areas with limited resources. The assay provides a reasonable approximation of efavirenz concentration in the majority of samples with a tendency to underestimate high concentrations. Agreement between tests evaluated in this study was clinically satisfactory for identification of low, normal and high efavirenz concentrations.

AB - INTRODUCTION: Therapeutic drug monitoring (TDM) may improve antiretroviral efficacy through adjustment of individual drug administration. This could result in reduced toxicity, prevent drug resistance, and aid management of drug-drug interactions. However, most measurement methods are too costly to be implemented in resource-limited settings. This study evaluated a commercially available immunoassay for measurement of plasma efavirenz.METHODS: The immunoassay-based method was applied to measure efavirenz using a readily available Humastar 80 chemistry analyzer. We compared plasma efavirenz concentrations measured by the immunoassay with liquid chromatography tandem mass spectrometry (LC-MS/MS) (reference method) in 315 plasma samples collected from HIV patients on treatment. Concentrations were categorized as suboptimal<1 µg/ml, normal 1-4 µg/ml or high>4 µg/ml. Agreement between results of the methods was assessed via Bland-Altman plot and κ statistic values.RESULTS: The median Interquartile range (IQR) efavirenz concentration was 2.8 (1.9; 4.5) µg/ml measured by the LC-MS/MS method and 2.5 (1.8; 3.9) µg/ml by the immunoassay and the results were well correlated (ρ=0.94). The limits of agreement assessed by Bland-Altman plots were -2.54; 1.70 µg/ml. Although immunoassay underestimated high concentrations, it had good agreement for classification into low, normal or high concentrations (K=0.74).CONCLUSIONS: The immunoassay is a feasible alternative to determine efavirenz in areas with limited resources. The assay provides a reasonable approximation of efavirenz concentration in the majority of samples with a tendency to underestimate high concentrations. Agreement between tests evaluated in this study was clinically satisfactory for identification of low, normal and high efavirenz concentrations.

U2 - 10.7448/IAS.17.1.18979

DO - 10.7448/IAS.17.1.18979

M3 - Journal article

C2 - 24909561

VL - 17

JO - International AIDS Society. Journal

JF - International AIDS Society. Journal

SN - 1758-2652

M1 - 18979

ER -

ID: 119650998